BRPI0609704B1 - compostos derivados de fosforamidato, seus usos, composições farmacêuticas que os compreendem, métodos de preparação das referidas composições e processo para preparação de um composto - Google Patents
compostos derivados de fosforamidato, seus usos, composições farmacêuticas que os compreendem, métodos de preparação das referidas composições e processo para preparação de um composto Download PDFInfo
- Publication number
- BRPI0609704B1 BRPI0609704B1 BRPI0609704-9A BRPI0609704A BRPI0609704B1 BR PI0609704 B1 BRPI0609704 B1 BR PI0609704B1 BR PI0609704 A BRPI0609704 A BR PI0609704A BR PI0609704 B1 BRPI0609704 B1 BR PI0609704B1
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- compound according
- fact
- group
- 6alkyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 101
- 238000000034 method Methods 0.000 title claims abstract description 17
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 12
- 239000000203 mixture Substances 0.000 title claims description 15
- 238000004519 manufacturing process Methods 0.000 title claims description 6
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 title abstract description 4
- -1 nucleoside compounds Chemical class 0.000 claims abstract description 28
- 208000032839 leukemia Diseases 0.000 claims abstract description 11
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 10
- 201000011510 cancer Diseases 0.000 claims abstract description 8
- 125000001424 substituent group Chemical group 0.000 claims description 29
- 239000000460 chlorine Substances 0.000 claims description 24
- 229910019142 PO4 Inorganic materials 0.000 claims description 19
- 238000006243 chemical reaction Methods 0.000 claims description 19
- 238000011282 treatment Methods 0.000 claims description 19
- 229910052801 chlorine Inorganic materials 0.000 claims description 18
- 229910052739 hydrogen Inorganic materials 0.000 claims description 18
- 239000010452 phosphate Substances 0.000 claims description 17
- 125000004432 carbon atom Chemical group C* 0.000 claims description 16
- 229910052731 fluorine Inorganic materials 0.000 claims description 14
- 229910052794 bromium Inorganic materials 0.000 claims description 12
- 229910052760 oxygen Inorganic materials 0.000 claims description 12
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 11
- 125000000623 heterocyclic group Chemical group 0.000 claims description 11
- 150000003839 salts Chemical class 0.000 claims description 11
- 238000011321 prophylaxis Methods 0.000 claims description 10
- UENGBOCGGKLVJJ-UHFFFAOYSA-N 2-chloro-1-(2,4-difluorophenyl)ethanone Chemical compound FC1=CC=C(C(=O)CCl)C(F)=C1 UENGBOCGGKLVJJ-UHFFFAOYSA-N 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 9
- 150000002148 esters Chemical class 0.000 claims description 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 9
- 229910003204 NH2 Inorganic materials 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 8
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 7
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 7
- 239000003085 diluting agent Substances 0.000 claims description 7
- 229910052740 iodine Inorganic materials 0.000 claims description 7
- 229910052717 sulfur Inorganic materials 0.000 claims description 7
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims description 6
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 6
- 229910006069 SO3H Inorganic materials 0.000 claims description 6
- 125000002252 acyl group Chemical group 0.000 claims description 6
- 125000004423 acyloxy group Chemical group 0.000 claims description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 6
- 125000001624 naphthyl group Chemical group 0.000 claims description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 6
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 claims description 6
- 150000003573 thiols Chemical class 0.000 claims description 6
- 125000006651 (C3-C20) cycloalkyl group Chemical group 0.000 claims description 5
- 235000001014 amino acid Nutrition 0.000 claims description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
- 239000003981 vehicle Substances 0.000 claims description 5
- 125000003837 (C1-C20) alkyl group Chemical group 0.000 claims description 4
- 125000003860 C1-C20 alkoxy group Chemical group 0.000 claims description 4
- 125000003358 C2-C20 alkenyl group Chemical group 0.000 claims description 4
- 150000001413 amino acids Chemical class 0.000 claims description 4
- 125000004076 pyridyl group Chemical group 0.000 claims description 4
- 239000012453 solvate Substances 0.000 claims description 4
- 125000006705 (C5-C7) cycloalkyl group Chemical group 0.000 claims description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 3
- 235000004279 alanine Nutrition 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 125000005493 quinolyl group Chemical group 0.000 claims description 3
- 125000006649 (C2-C20) alkynyl group Chemical group 0.000 claims description 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 2
- 229920002472 Starch Polymers 0.000 claims description 2
- 238000000605 extraction Methods 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 abstract description 22
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 abstract description 16
- 229960002436 cladribine Drugs 0.000 abstract description 12
- WDDPHFBMKLOVOX-AYQXTPAHSA-N clofarabine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F WDDPHFBMKLOVOX-AYQXTPAHSA-N 0.000 abstract description 10
- 229960000928 clofarabine Drugs 0.000 abstract description 10
- 239000002777 nucleoside Substances 0.000 abstract description 6
- 238000002360 preparation method Methods 0.000 abstract description 5
- 241000282414 Homo sapiens Species 0.000 abstract description 4
- 125000001072 heteroaryl group Chemical group 0.000 abstract description 4
- 230000001225 therapeutic effect Effects 0.000 abstract description 2
- 150000008298 phosphoramidates Chemical class 0.000 abstract 1
- 125000004437 phosphorous atom Chemical group 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 72
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 34
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 33
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 28
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 22
- UUFQTNFCRMXOAE-UHFFFAOYSA-N 1-methylmethylene Chemical compound C[CH] UUFQTNFCRMXOAE-UHFFFAOYSA-N 0.000 description 18
- 239000002904 solvent Substances 0.000 description 17
- 101100167062 Caenorhabditis elegans chch-3 gene Proteins 0.000 description 14
- 125000000217 alkyl group Chemical group 0.000 description 14
- 125000004433 nitrogen atom Chemical group N* 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 11
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 10
- 238000005160 1H NMR spectroscopy Methods 0.000 description 9
- 238000004679 31P NMR spectroscopy Methods 0.000 description 9
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 125000003545 alkoxy group Chemical group 0.000 description 9
- 235000021317 phosphate Nutrition 0.000 description 9
- MCTWTZJPVLRJOU-UHFFFAOYSA-N 1-methyl-1H-imidazole Chemical compound CN1C=CN=C1 MCTWTZJPVLRJOU-UHFFFAOYSA-N 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 125000004122 cyclic group Chemical group 0.000 description 8
- 239000000651 prodrug Substances 0.000 description 8
- 229940002612 prodrug Drugs 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 238000003818 flash chromatography Methods 0.000 description 7
- 229960000390 fludarabine Drugs 0.000 description 7
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 7
- 239000006260 foam Substances 0.000 description 7
- 125000005842 heteroatom Chemical group 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 6
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 230000001093 anti-cancer Effects 0.000 description 6
- 125000002619 bicyclic group Chemical group 0.000 description 6
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 125000002015 acyclic group Chemical group 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 238000010828 elution Methods 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 238000010791 quenching Methods 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 239000003039 volatile agent Substances 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 125000003342 alkenyl group Chemical group 0.000 description 4
- 229940024606 amino acid Drugs 0.000 description 4
- 239000007900 aqueous suspension Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000011737 fluorine Substances 0.000 description 4
- 150000003833 nucleoside derivatives Chemical class 0.000 description 4
- 125000004430 oxygen atom Chemical group O* 0.000 description 4
- 238000012746 preparative thin layer chromatography Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
- 125000000304 alkynyl group Chemical group 0.000 description 3
- 230000000719 anti-leukaemic effect Effects 0.000 description 3
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 3
- 125000000753 cycloalkyl group Chemical group 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 238000005755 formation reaction Methods 0.000 description 3
- 239000012442 inert solvent Substances 0.000 description 3
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 3
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical compound [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 3
- 125000004434 sulfur atom Chemical group 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- 238000004293 19F NMR spectroscopy Methods 0.000 description 2
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
- 125000002373 5 membered heterocyclic group Chemical group 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 2
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- GZUXJHMPEANEGY-UHFFFAOYSA-N bromomethane Chemical compound BrC GZUXJHMPEANEGY-UHFFFAOYSA-N 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical compound C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 2
- 238000002953 preparative HPLC Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 2
- 229960001860 salicylate Drugs 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- HBUBKKRHXORPQB-FJFJXFQQSA-N (2R,3S,4S,5R)-2-(6-amino-2-fluoro-9-purinyl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O HBUBKKRHXORPQB-FJFJXFQQSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- 125000000027 (C1-C10) alkoxy group Chemical group 0.000 description 1
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 description 1
- 125000002733 (C1-C6) fluoroalkyl group Chemical group 0.000 description 1
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
- 125000005926 1,2-dimethylbutyloxy group Chemical group 0.000 description 1
- JPRPJUMQRZTTED-UHFFFAOYSA-N 1,3-dioxolanyl Chemical group [CH]1OCCO1 JPRPJUMQRZTTED-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- TYOJIXXRBLDIAN-VCXZVJRYSA-N C12=NC(N)(N)NC(O)(Cl)C2=NCN1[C@H]1C[C@H](O)[C@@H](CO)O1 Chemical compound C12=NC(N)(N)NC(O)(Cl)C2=NCN1[C@H]1C[C@H](O)[C@@H](CO)O1 TYOJIXXRBLDIAN-VCXZVJRYSA-N 0.000 description 1
- 0 CCCC(C)(*IC)N(C(*)(C(O)OI)I)I Chemical compound CCCC(C)(*IC)N(C(*)(C(O)OI)I)I 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- KMTRUDSVKNLOMY-UHFFFAOYSA-N Ethylene carbonate Chemical compound O=C1OCCO1 KMTRUDSVKNLOMY-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 238000000719 MTS assay Methods 0.000 description 1
- 231100000070 MTS assay Toxicity 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 1
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 229920002253 Tannate Polymers 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
- 125000004171 alkoxy aryl group Chemical group 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 150000001508 asparagines Chemical class 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 238000004296 chiral HPLC Methods 0.000 description 1
- ITVPBBDAZKBMRP-UHFFFAOYSA-N chloro-dioxido-oxo-$l^{5}-phosphane;hydron Chemical compound OP(O)(Cl)=O ITVPBBDAZKBMRP-UHFFFAOYSA-N 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 229960002023 chloroprocaine Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 238000010549 co-Evaporation Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000006165 cyclic alkyl group Chemical group 0.000 description 1
- 125000004367 cycloalkylaryl group Chemical group 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- ACYGYJFTZSAZKR-UHFFFAOYSA-J dicalcium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Ca+2].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O ACYGYJFTZSAZKR-UHFFFAOYSA-J 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229940009662 edetate Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 229950007655 esilate Drugs 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 235000004554 glutamine Nutrition 0.000 description 1
- 229940074045 glyceryl distearate Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 201000009277 hairy cell leukemia Diseases 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 235000014304 histidine Nutrition 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 229950000886 isetionate Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 208000003747 lymphoid leukemia Diseases 0.000 description 1
- 238000012792 lyophilization process Methods 0.000 description 1
- 235000018977 lysine Nutrition 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 235000006109 methionine Nutrition 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- 229940102396 methyl bromide Drugs 0.000 description 1
- LRMHVVPPGGOAJQ-UHFFFAOYSA-N methyl nitrate Chemical compound CO[N+]([O-])=O LRMHVVPPGGOAJQ-UHFFFAOYSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 229940014662 pantothenate Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000004237 preparative chromatography Methods 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 description 1
- RUOJZAUFBMNUDX-UHFFFAOYSA-N propylene carbonate Chemical compound CC1COC(=O)O1 RUOJZAUFBMNUDX-UHFFFAOYSA-N 0.000 description 1
- 239000002212 purine nucleoside Substances 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 235000004400 serine Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 238000003797 solvolysis reaction Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 235000008521 threonine Nutrition 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- ABDKAPXRBAPSQN-UHFFFAOYSA-N veratrole Chemical compound COC1=CC=CC=C1OC ABDKAPXRBAPSQN-UHFFFAOYSA-N 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
X = Cl, Y=NH2 'isocladribina'
X = NH2, Y= Cl clofarabina
X = NH2, Y = F, fludarabina
cada um de X e Z é independentemente selecionado de H, OH, F, Cl, Br, I, C1-6alquila e NR5R6, onde cada um de R5 e R6 é independentemente selecionado de H e C1-6alquila;
Y é selecionado de H, OH, F, Cl, Br, I, C1-6alquila, C2-8alquinila, NR5R6, onde cada um de R5 e R6 é independentemente selecionado de H e C1-6 alquila;
cada um de T e T' é independentemente selecionado de H, F e OH, contanto que apenas um de T e T' possa ser OH;
Q é selecionado de O, S e CR7R8, onde R7 e R8 são independentemente selecionados de H e C1-6alquila,
Ar é selecionado de C6-30arila e C6-30heteroarila, cada um dos quais é opcionalmente substituído;
cada um de R1 e R2 é independentemente selecionado de H e do grupo consistindo em C1-20alquila, C2-20alquenila, C1-20alcóxi, C1- 20alcóxiC1-20alquila, C1-20alcóxiC6-30arila, C2-20alquinila, C3- 20cicloalquilC6-30arila, C6-30arilóxi e C5-20heterociclila, qualquer um dos quais é opcionalmente substituído;
cada um de R3 e R4 é independentemente selecionado de H e do grupo consistindo em C1-20alquila, C2-20alquenila, C1-20alcóxi, C1- 20alcóxiC1-20alquila, C1-20alcóxiC6-30arila, C2-20alquinila, C3-20cicloalquilC6-30arila, C6-30arilóxi e C5-20heterociclila, qualquer um dos quais é opcionalmente substituído; e
sais, solvatos e pró-fármacos farmaceuticamente aceitáveis dos mesmos.
Onde um de T e T' é F, o outro de T e T' é, adequadamente, H.
X = NH2, Y = Cl, Z = H, Q = O e T = T' = H e são, assim, derivados de cladribina;
X = Cl, Y = NH2, Z = H, Q = O e T = T' = H e são, assim, derivados de isocladribina;
X = NH2, Y = F, Z = H, Q = O e T = T = H e são, assim, derivados de fludarabina;
X = NH2, Y = Cl, Z = H, Q = O, T = F e T' = H e são, assim, derivados de clofarabina; e
X = NH2, Y = C2-8alquinila, mais preferivelmente C2-6alquinila, Z = H5 Q = O, T = H e T' = OH.
Exemplos incluem, e não estão limitados a, piridila e quinolila.
31P-RMN (CDCl3, 121 MHz): δ 4,56, 4,21, 1H-RMN (CDCl3, 300 MHz): δ 8,14, 8,07 (1H, 2s, H-8), 7,52-7,29 (5H, m, Ph), 656-6,50 (1H, m, H-1'), 6,18-6,01 (1H, bs, NH2), 4,90-4,77 (1H, m, H-3'), 4,46-4,56 (2H, m, H5'), 4,32-4,26 (1H, m, H-4'), 4,22-4,02 (1H, m, CHNH), 3,85,3,83 (3H, 2s, CH3O), 2,92-2,61 (2H, m, H-2'), 1,56-1,44 (3H, m, CH3CH).
31P-RMN (MeOH, 121 MHz): δ 5,11,4,81, 1H-RMN (MeOH, 300 MHz): δ 8,12, 8,10 (1H, 2s, H-8), 7,23-7,04 (10H, m, PhO, PhCH2), 6,30-6,24 (1H, m, H-1'), 5,04-5,00 (2H, m, PhCH2), 4,52-4,48 (1H, m, H-3'), 4,29- 4,15 (2H, m, H-5'), 4,08-4,04 (1H, m, H-4'), 3,91-3,81 (1H, m, CHNH), 2,63-2,54 (1H, m, um de H-2'), 2,41-2,33 (1H, m, um de H-2'), 1,24- 1,17 (3H, m, CHCH3). 13C-RMN (MeOD; 75 MHz): δ 20,6, 20,8 (CH3), 41,2 (C-2'), 52,0, 52,1 (CHCH3), 67,7, 68,1, 68,2, 68,3 (C-5', CH2Ph), 72,6 (C-3'), 86,2, 86,4 (C-1'), 87,2, 87,3 (C-4'), 121,7, 121,8, 126,5, 129,6, 129,7, 129,9, 131,1, 137,6, 141,5 (C-5, C-8, PhCH2, PhO,"ipso" PhCH2), 151,8, 151,9 (C-6), 152,4, 152,5 ("ipso" PhO), 155,7, 155,8 (C-2), 158,4 (C-4), 175,0, 175,2 (COOCH2Ph).
MISTURADA (CPF210)
31P-RMN (CDCl3, 202 MHz): δ 3,64,3,23 (int.: 1,00, 0,97).
HPLC: Rt 8,92, 9,59 min. 1H-RMN (CDCl3, 500 MHz): δ 8,00-7,98 (1H, m, H-8 Naft), 7,86 (0, 5 H, s, um de H-8 de um diastereoisômero), 7,77 (1H, d, H-5 Naft, 3J = 7,4 Hz), 7,75 (0,5 H, s, um de H-8 de um diastereoisômero), 7,56 (1H, d, H-4 Naft, 3J = 8,3 Hz), 7,44-7,40 (3H, m, H-2 Naft, H-6 Naft, H-7 Naft), 7,31-7,15 (6H, m, H-3 Naft, Ph), 6,25- 6,21 (1H, m, H-1'), 5,73 (2H, bs, NH2), 5,04 (1H, s, CH2Ph de um diastereoisômero), 4,97 (0, 5Η, d, 2J = 12,2 Hz, um CH2Ph de um diastereoisômero), 4,94 (0,5Η, d, 2J = 12,2 Hz, um CH2Ph de um diastereoisômero), 4,57-4,54 (0,5H, m, H-3 ' de um diastereoisômero), 4,49-4,46 (0, 5H, m, H-3' de um diastereoisômero), 4,34-4,23 (2H, m, H-5'), 4,11-4,00 (2H, m, H- 4', CHNH), 3,91 (0,5H, CHNH de um diastereoisômero), 3,90 (0, 5H, CHNH de um diastereoisômero), 3,13 (0,5H, OH de um diastereoisômero), 3,01 (0,5H, OH de um diastereoisômero), 2,56-2,51 (0, 5H, m, um H-2' de um diastereoisômero), 2,43-2,29 (1,5H, m, três H-2'), 1,27-1,24 (3H, 2d, CHCH3).
13C-RMN (CDCl3; 125 MHz): δ 19,7, 19,8 (CH3), 38,8 (C-2'), 49,4, 49,5 (CHCH3), 64,8, 66,2, 66,3 (C-5',CH2Ph), 69,8 (C-3'), 83,0 (C-1'), 83,9, 84,0 (C-4'), 113,9, 114,0 (C-2 Naft), 117,6, 120,2, 120,3, 123,9, 124,5, 125,2, 125,4, 125,5, 125,7, 126,8, 127,1, 127,4, 127,5, 127,6 (C-5, C8, PhCH2, C-5a Naft, C-3 Naft, C-4 Naft, C-5 Naft, C-6 Naft, C-7 Naft, C-8 Naft, C-8a Naft), 133,6, 133,7, 134,1 ("ipso" PhCH2, C-4a Naft), 145,3 (C-1 Naft), 149,3 (C-6), 153,0 (C-2), 155,13 (C-4), 172,4 (COOCH2Ph).
ELUIÇÃO RÁPIDA (cpf211)
31P-RMN (CDCl3, 202 MHz): δ 3,60, 3,22 (int.: 4,87, 1,00). HPLC: Rt 7,59, 8,92 min. 1H-RMN (CDCl3, 500 MHz): δ 8,03 (1H, d, 3J = 7,5 Hz, H-8 Naft), 7,92 (0, 2H, s, um de H-8 do diastereoisômero menor), 7,80 (0,8H, s, H-8), 7,79 (1H, d, 3J = 7,4 Hz, H-5 Naft), 7,61 (1H, d, H-4 Naft, 3J = 8,3 Hz), 7,47-7,44 (3H, m, H-2 Naft, H-6 Naft, H-7 Naft), 7,35-7,12 (6H, m, H-3 Naft, Ph), 6,29-6,26 (1H, m, H-1'), 5,88 (2H, bs, NH2), 5,08 (0, 4H, s, CH2Ph do diastereoisômero menor), 5,05, 4,97 (1,6Η, 2d, 2J = 12,2 Hz, CH2Ph), 4,61-4,58 (0, 2H, m, H-3' do diastereoisômero menor), 4,54-4,51 (0, 8H, m, H-3'), 4,36-4,32 (2H, m, H- 5'), 4,12-4,06 (2,2H, m, H-4', CHNH, CHNH do diastereoisômero menor), 3,82 (0, 8Η, CHNH), 3,32 (0,2Η, OH do diastereoisômero menor), 3,25 (0,8H, OH), 2,58-2,53 (0,2H, m, um H-2' do diastereoisômero menor), 2,46-2,42 (0,2H, m, um H-2' do diastereoisômero menor), 2,41-2,33 (1,6H, m, H-2'), 1,31-1,29 (3H, 2d, CHCH3).
ELUIÇÃO LENTA (cpf212)
31P-RMN (CDCl3, 202 MHz): δ 3,64,3,25 (int.: 1,00, 28,15). HPLC: Rt 9,59, 10,92 min. 1H-RMN (CDCl3, 500 MHz): δ 7,99-7,97 (1H, dd, H-8 Naft), 7,87 (1H, s, H-8), 7,77-7,74 (1H, m, H-5 Naft), 7,57 (1H, d, H-4 Naft, 3J = 8,3 Hz), 7,44-7,40 (3H, m, H-2 Naft, H-6 Naft, H-7 Naft), 7,29-7,20 (6H, m, H-3 Naft, Ph), 6,23 (1H, m, H-1'), 5,81 (2H, bs, NH2), 5,03 (2H, s, CH2Ph), 5,00, 4,92 (d, 2J = 12,3 Hz, CH2Ph do diastereoisômero menor), 4,58-4,55 (1H, m, H-3'), 4,49,4,48 (m, H-3' do diastereoisômero menor), 4,34-4,23 (2H, m, H-5'), 4,08-3,99 (3H, m, H-4', CHNH, CHNH), 3,78 (CHNH do diastereoisômero menor), 3,31 (1H, bs, OH), 2,56-2,50 (1H, m, um H-2'), 2,42- 2,38 (1H, m, um H-2'), 2,37-2,31 (m, H-2' do diastereoisômero menor), 1,26 (3H, 2d, CHCH3).
1H-RMN (CDCl3, 500 MHz): δ 8,14-8,10 (1H, m, H-5 Naft), 7,99-7,96 (1H, m, H-8 Naft), 7,88 (0,5H, s, um de H-8 de um diastereoisômero), 7,82 (0,5 H, s, um de H-8 de um diastereoisômero), 7,54-7,49 (1H, m, H-6 Naft), 7,47-7,40 (1H, m, H-7 Naft), 7,32-7,14 (7H, m, H-2 Naft, H-3 Naft, Ph), 6,25-6,22 (1H, m, H-1'), 6,04 (2H, bs, NH2), 5,00 (1H, s, CH2Ph de um diastereoisômero), 4,97 (0, 5H, d, 2J = 12,2 Hz, um CH2Ph de um diastereoisômero), 4,90 (0,5H, d, 2J = 12,2 Hz, um CH2Ph de um diastereoisômero), 4,59-4,54 (1H, m, H-3'), 4,33-4,19 (2,5H, m, H-5', CHNH de um diastereoisômero), 4,08-3,96 (2,5H, m, H4', CHNH, CHNH de um diastereoisômero), 3,61,3,57 (1H, 2 bs, OH3'), 3,01 (0, 5H, OH de um diastereoisômero), 2,59-2,34 (2H, m, H-2'), 1,25-1,23 (3H, m, CHCH3). 13C-RMN (CDCl3; 125 MHz): 20,8 (CH3), 39,7 (C-2'), 50, 5 (CHCH3), 66,2,66,3 (C-5'), 67,4 (CH2Ph), 71,0 (C-3'), 84,1 (C-1'), 84,9, 85,0, 85,1 (C-4'),114,8, 114,9, 115,1, 118,8, 121,8, 124,7, 125,5, 127,2, 127,8, 128,1, 128,3, 128,5, 128,6, 128,7 (C- 2 Naft, C-3 Naft, C-4 Naft, C-5 Naft, C-6 Naft, C-7 Naft, C-8 Naft, C-8a Naft, Ph), 131,6 (C-4a), 135,0 ("ipso" PhCH2), 139,3, 139,4 (C-8), 145,3, 145,4 (C-1 Naft), 150,4 (C-6), 154,1 (C-2), 156,1 (C-4), 173,3 (COOCH2Ph).
31P-RMN (MeOH, 121 MHz): δ 5,33, 5,00, 1H-RMN (MeOH, 300 MHz): δ 8,17, 8,16 (1H, 2s, H-8), 7,32-7,13 (10H, m, PhO, PhCH2), 6,37, 6,32 (1H, 2d, H-1'), 5,11-5,06 (2H, m, PhCH2), 4,61-4,56 (1H, m, H-3'), 4,41- 4,20 (1H, m, H-5'), 4,18-4,08 (1H, m, H-4'), 4,00-3,89 (1H, m, CHNH), 2,84-2,68 (1H, m, um de H-2'), 2,41-2,30 (1H, m, um de H-2'), 1,30-1,24 (3H, m, CHCH3). 13C-RMN (MeOD; 75 MHz): δ 20,6, 20,7, 20,8 (CH3), 40,4, 40,7 (C-2'), 51,9, 52,1 (CHCH3), 67,8, 68,1, 68,4 (C-5', CH2Ph), 72,8 (C-3'), 86,4 (C-1'), 87,1, 87,3, 87,4 (C-4'), 121,7, 121,8, 125,8, 126,5, 129,7, 129,9, 131,1 (PhCH2, PhO), 137,5, 137,6 ("ipso" PhCH2), 143,2, 143,3 (C-8), 152,0 (C-6), 152,4, 152,5 ("ipso" PhO), 155,0, 155,1 (C-2), 161,9 (C-4), 175,0, 175,2 (COOCH2Ph).
19F-RMN (MeOD; 282 MHz): δ -54,04, 31P-RMN (MeOD; 121 MHz): δ 4,99, 1H-RMN (MeOD; 300 MHz): δ 8,22, 8,20 (1H, 2xs, H-8), 7,38- 7,19 (5H, m, PhO), 6,33, 6,32 ((1H, 2xd, 3J = 3,4 Hz, H-1 '0, 4,89-4,27 (4H, m, H-2' +H-5' +H-4'), 4,17-4,03 (1H, m, H-3'), 4,00-3,85 ((1H, m, CHCH3), 3,66-3,65 ((3H, 2xs, CH3O), 1,34, 1,29 (3H, 2xd, 3J = 7,1 Hz, CH3CH). 13C-RMN (MeOD; 75 MHz): 20,7, 20,8, 20,9 (CH3CH), 51,9 (CH3CH), 53,1, 53,2 (CH3O), 67,4, 67,5, 67,8, 67,9 (C-5'), 77,3, 77,4, 77,6 (C-4' +C-2'), 84,0, 84,1, 84,2, 84,3 (C-3'), 86,5, 86,7 (C-1'), 118,2 (adenosina-C), 121,8, 121,9 ('m', PhO), 126,5 ('p', PhO), 131,1 ('ipso', PhO), 142,9, 143,0 ( 5J = 2,9 Hz, C-8), 142,8, 142,9 (C-8), 152,4, 152,5, 152,6 (adenosina-C + 'ipso' PhO), 159,2, 159,4, 159,6, 162,4 (adenosina-C), 175,7, 175,8, 175,9 (COOMe).
Clofarabina-5'-[fenil-(benzóxi-L-alaninil)]fosfato
31P-RMN (MeOD, 202 MHz): δ 3,77, 3,64; 19F-RMN (MeOD, 470 MHz): δ -198,98, -199,01; 1H-RMN (MeOD, 500 MHz): δ 8,17, 8,16 (1H, 2s, H-8), 7,34-7,15 (10H, m, PhO, PhCH2), 6,46-6,40 (1H, m, H-1'), 5,21- 5,07 (3H, m, H-2', PhCH2), 4,56, 4,52 (1H, 2s, H-3'), 4,40-4,39 (2H, m, H-5'), 4,19-4,16 (1H, m, H-4'), 4,04-4,01 (1H, m, CHCH3), 1,35, 1,33 (3H, 2d, 3J = 8,5 Hz, CHCH3); 13C-RMN (MeOD, 75 MHz): 20,3, 20,4, 20,5 (CH3), 51,6, 51,8 (CHCH3), 66,8, 67,1 (C-5'), 68,0 (CH2Ph), 75,0, 75,1, 75,3 (C-3'), 83,6, 83,7, 83,8 (C-4'), 84,3, 84,4, 84,5 (C-1'), 95,6, 97,2 (C-2'), 118,6 (C-5), 121,4, 121,5, 126,2, 129,2, 129,3, 129,6, 130,8 (PhO, CH2Ph), 137,2 ('ipso' CH2Ph), 141,7, 141,8 (C-8), 151,7, 152,2 ('ipso' PhO, C-6), 155,6 (C-4), 158,1 (C-2), 174,8, 174,9 (CO2CH2Ph). HPLC (H2O/CH3CN de 100/0 a 0/100 em 20 min): tR 11,76 min. ESI MS (positivo): 621 [M].
Claims (26)
- Composto, caracterizado pelo fato de que apresenta a fórmula I:em que:
cada um de X e Z é independentemente selecionado de H, OH, F, Cl, Br, I, C1-6alquila e NR5R6, em que cada um de R5 e R6 é independentemente selecionado de H e C1-6alquila;
Y é selecionado de OH, F, Cl, Br, I, C1-6alquila, C2-8alquinila, NR5R6, em que cada um de R5 e R6 é independentemente selecionado de H e C1-6 alquila;
cada um de T e T' é independentemente selecionado de H, F e OH, contanto que apenas um de T e T' possa ser OH;
Q é selecionado de O, S e CR7R8, em que R7 e R8 são independentemente selecionados de H e C1-6alquila,
Ar é selecionado de C6-30arila e C6-30heteroarila, cada uma das quais é opcionalmente substituída com um ou mais substituintes selecionados independentemente do grupo que consiste em hidroxi, acila, aciloxi, nitro, amino, SO3H, SH, SR', em que R' é selecionado independentemente do mesmo grupo que R1, carboxil, C1-6ésteres, C1-6aldeído, ciano, C1-6alquilamino, C1-6dialquilamino, tiol, cloro, bromo, fluoro, iodo, C1-6alquil, C2-6alquenil, C1-6alcoxi-C1-6alquil, C1-6alcoxi-C5-10aril, C5-7cicloalquil, C5-11cicloalquil-C1-6alquil, C5-7cicloalquenil, C5-7cicloalquinil, C5-11arilC1-6alquil, C1-6alquilC5-11aril, C5-11aril, C11- 6fluoroalquil e C2-6fluoroalquenil;
cada um de R1 e R2 é independentemente selecionado de H e do grupo consistindo em C1-20alquila, C2-20alquenila, C1-20alcóxi, C1- 20alcóxiC1-20alquila, C1-20alcóxiC6-30arila, C2-20alquinila, C3- 20cicloalquilC6-30arila, C6-30arilóxi e C5-20heterociclila, qualquer um dos quais é opcionalmente substituído;
cada um de R3 e R4 é independentemente selecionado de H e do grupo consistindo em C1-20alquila, C2-20alquenila, C1-20alcóxi, C1- 20alcóxiC1-20alquila, C1-20alcóxiC6-30arila, C2-20alquinila, C3-20cicloalquil C6-30arila, C6-30arilóxi e C5-20heterociclila, qualquer um dos quais é opcionalmente substituído;
quaisquer substituintes opcionais em R1, R2, R3 e R4 sendo um ou mais substituintes selecionados independentemente do grupo que consiste em hidroxi, acil, aciloxi, nitro, amino, amido, SO3H, SH, SR', em que R' é selecionado independentemente a partir de o mesmo grupo que R1, carboxi, C1-6ésteres, C1-6aldeído, ciano, C1-6alquilamino, C1-6dialquilamino, tiol, cloro, bromo, bromo, fluoro, iodo, C5-7cicloalquil, C5-7cicloalquenil, C5-7cicloalquinil, C5-11aril, C5-11arilC1-6alquil e C5- 20heterociclil;
e sais e solvatos farmaceuticamente aceitáveis dos mesmos;
contanto que, ao mesmo tempo, X não seja NH2, Z não seja H, Y não seja H, T não seja H, T’ não seja OH, Q não seja O, Ar não seja C6H5, R1 não seja CH3, R2 não seja H, R3 não seja CH3 e R4 não seja H. - Composto de acordo com a reivindicação 1, caracterizado pelo fato de que cada um de X e Z é independentemente selecionado de OH, F, Cl e NH2 e Y é selecionado de H, OH, F, Cl, NH2 e C2-8 alquinila.
- Composto de acordo com a reivindicação 2, caracterizado pelo fato de que X é NH2, Y é Cl e Z é H.
- Composto de acordo com a reivindicação 2, caracterizado pelo fato de que X é Cl, Y é NH2 e Z é H.
- Composto de acordo com a reivindicação 2, caracterizado pelo fato de que X é NH2, Y é F e Z é H.
- Composto de acordo com qualquer uma das reivindicações 1 a 5, caracterizado pelo fato de que T e T' são, cada um, H.
- Composto de acordo com qualquer uma das reivindicações 1 a 5, caracterizado pelo fato de que um ou ambos de T e T' são F.
- Composto de acordo com a reivindicação 2, caracterizado pelo fato de que X é NH2, Y é C2-8alquinila, Z é H, T é H e T' é OH.
- Composto de acordo com qualquer uma das reivindicações 1 a 8, caracterizado pelo fato de que Q é O.
- Composto de acordo com qualquer uma das reivindicações 1 a 9, caracterizado pelo fato de que R4 é H.
- Composto de acordo com qualquer uma das reivindicações 1 a 10, caracterizado pelo fato de que R1 e R2 são selecionados de modo que a porção -N-CR1R2-COO- corresponda a aquela de um aminoácido natural.
- Composto de acordo com qualquer uma das reivindicações 1 a 11, caracterizado pelo fato de que cada um de R1 e R2 é independentemente selecionado de Me e H.
- Composto de acordo com a reivindicação 12, caracterizado pelo fato de que um de R1 e R2 é Me e um de R1 e R2 é H, de modo que o átomo de C trazendo R1 e R2 tem quiralidade L, como na alanina natural.
- Composto de acordo com qualquer uma das reivindicações 1 a 13, caracterizado pelo fato de que Ar é não substituído.
- Composto de acordo com qualquer uma das reivindicações 1 a 13, caracterizado pelo fato de que Ar é substituído por um, dois, três, quatro, cinco ou mais substituintes selecionados do grupo compreendendo porções de doação de elétrons e porções de extração de elétrons.
- Composto de acordo com qualquer uma das reivindicações 1 a 15, caracterizado pelo fato de que Ar é selecionado do grupo compreendendo fenila, piridila, naftila e quinolila, cada um dos quais podendo ser substituído ou não substituído.
- Composto de acordo com qualquer uma das reivindicações 1 a 16, caracterizado pelo fato de que compreende o diastereoisômero Rp, o diastereoisômero Sp, ou uma mistura dos diastereoisômeros Rp e Sp.
- Composto de acordo com a reivindicação 1, caracterizado pelo fato de que é selecionado do grupo compreendendo:
2-cloro-2'-deoxiadenosina-5'-[fenil-(metóxi-L-alaninil)]-fosfato;
2-cloro-2'-deoxiadenosina-5'-[fenil-(benzóxi-L-alaninil)]-fosfato;
2-cloro-2'-deoxiadenosina-5'-[1-naftil-(metóxi-L-alaninil)]-fosfato;
2-cloro-2'-deoxiadenosina-5'-[4-cloro-1-naftil-(benzóxi-L-alaninil)]-fosfato;
2-amino-6-cloropurina-2'-deoxirribosídeo-5'-[fenil-(metóxi-L-alaninil)]-[fosfato; e
9-β-D-aribinofuranosil-2-fluoroadenina-5'-[fenil-(metóxi-L-alaninil)]fosfato. - Composto de acordo com a reivindação 1, caracterizado pelo fato de que é o composto é 2-cloro-2'-beta-flúor-2'- deoxiadenosina-5'-[fenil-(benzóxi-L-(alaninil)]-fosfato.
- Uso de um composto como definido em qualquer uma das reivindicações 1 a 18, incluindo a opção de Y ser H, , caracterizado pelo fato de que é na fabricação de um medicamento para a profilaxia ou tratamento de câncer, de preferência um medicamento para a profilaxia ou tratamento de leucemia.
- Composição farmacêutica, caracterizada pelo fato de que compreende um composto como definido em qualquer uma das reivindicações 1 a 18, em combinação com um veículo, diluente, ou excipiente farmaceuticamente aceitável.
- Método de preparação de uma composição farmacêutica, caracterizado pelo fato de que compreende a etapa de combinação de um composto como definido em qualquer uma das reivindicações 1 a 18, com um excipiente, veículo, ou diluente farmaceuticamente aceitável.
- Uso de um composto como definido na reivindicação 19, caracterizado pelo fato de que é na fabricação de um medicamento para a profilaxia ou tratamento de câncer, de preferência um medicamento para a profilaxia ou tratamento de leucemia.
- Composição farmacêutica, caracterizada pelo fato de que compreende um composto como definido na reivindicação 19, em combinação com um veículo, diluente, ou excipiente farmaceuticamente aceitável.
- Método de preparação de uma composição farmacêutica, caracterizado pelo fato de que compreende a etapa de combinação de um composto como definido na reivindicação 19, com um excipiente, veículo, ou diluente farmaceuticamente aceitável.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0505781.5 | 2005-03-21 | ||
GBGB0505781.5A GB0505781D0 (en) | 2005-03-21 | 2005-03-21 | Chemical compounds |
PCT/GB2006/000932 WO2006100439A1 (en) | 2005-03-21 | 2006-03-16 | Phosphoramidate derivatives of nucleoside compounds for use in the treatment of cancer |
Publications (3)
Publication Number | Publication Date |
---|---|
BRPI0609704A2 BRPI0609704A2 (pt) | 2010-04-20 |
BRPI0609704B1 true BRPI0609704B1 (pt) | 2020-12-01 |
BRPI0609704B8 BRPI0609704B8 (pt) | 2021-09-28 |
Family
ID=34531603
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0609704A BRPI0609704B8 (pt) | 2005-03-21 | 2006-03-16 | compostos derivados de fosforamidato, seus usos, composições farmacêuticas que os compreendem, métodos de preparação das referidas composições e processo para preparação de um composto |
Country Status (20)
Country | Link |
---|---|
US (1) | US8263575B2 (pt) |
EP (1) | EP1866324B1 (pt) |
JP (2) | JP5345381B2 (pt) |
CN (2) | CN101175763A (pt) |
AT (1) | ATE471334T1 (pt) |
AU (1) | AU2006226182C1 (pt) |
BR (1) | BRPI0609704B8 (pt) |
CA (1) | CA2602324C (pt) |
CY (1) | CY1111538T1 (pt) |
DE (1) | DE602006014949D1 (pt) |
DK (1) | DK1866324T3 (pt) |
ES (1) | ES2348741T3 (pt) |
GB (1) | GB0505781D0 (pt) |
IL (1) | IL186104A (pt) |
MX (1) | MX2007011666A (pt) |
PL (1) | PL1866324T3 (pt) |
PT (1) | PT1866324E (pt) |
SI (1) | SI1866324T1 (pt) |
WO (1) | WO2006100439A1 (pt) |
ZA (1) | ZA200709011B (pt) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0623493D0 (en) * | 2006-11-24 | 2007-01-03 | Univ Cardiff | Chemical compounds |
AU2012216500B2 (en) * | 2006-11-24 | 2013-06-20 | Katholieke Universiteit Leuven | Nucleoside aryl phosphoramidates and their use as anti-viral agents for the treatment of hepatitis C virus |
US8173621B2 (en) | 2008-06-11 | 2012-05-08 | Gilead Pharmasset Llc | Nucleoside cyclicphosphates |
EA201100851A1 (ru) | 2008-12-23 | 2012-04-30 | Фармассет, Инк. | Аналоги нуклеозидов |
CL2009002206A1 (es) | 2008-12-23 | 2011-08-26 | Gilead Pharmasset Llc | Compuestos derivados de pirrolo -(2-3-d]-pirimidin-7(6h)-tetrahidrofuran-2-il fosfonamidato, composicion farmaceutica; y su uso en el tratamiento de enfermedades virales. |
NZ593648A (en) | 2008-12-23 | 2013-09-27 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
PE20120013A1 (es) | 2009-01-09 | 2012-02-02 | Univ Cardiff | Fosforamidato derivados de guanosina compuestos nucleosidos para tratamiento de infecciones virales |
BR112012024884A2 (pt) | 2010-03-31 | 2016-10-18 | Gilead Pharmasset Llc | síntese estereosseletiva de ativos contendo fósforo |
GB201016855D0 (en) * | 2010-10-06 | 2010-11-17 | Nucana Biomed Ltd | Chemical compounds |
WO2012092484A2 (en) * | 2010-12-29 | 2012-07-05 | Inhibitex, Inc. | Substituted purine nucleosides, phosphoroamidate and phosphorodiamidate derivatives for treatment of viral infections |
US9095599B2 (en) | 2011-01-03 | 2015-08-04 | Nanjing Molecular Research, Inc. | O-(substituted benzyl) phosphoramidate compounds and therapeutic use |
CN104974206B (zh) * | 2011-03-01 | 2019-08-23 | 努卡那生物医药有限责任公司 | 用于治疗癌症的5-氟-2’-脱氧尿苷的氨基磷酸酯衍生物 |
WO2012125900A1 (en) | 2011-03-16 | 2012-09-20 | Enanta Pharmaceuticals, Inc. | 2'-allene-substituted nucleoside derivatives |
MX2015006195A (es) * | 2012-11-16 | 2015-12-08 | Univ Cardiff | Procedimiento para preparar profarmacos de nucleosidos. |
EP3004130B1 (en) | 2013-06-05 | 2019-08-07 | Idenix Pharmaceuticals LLC. | 1',4'-thio nucleosides for the treatment of hcv |
US10030044B2 (en) | 2013-11-27 | 2018-07-24 | Idenix Pharmaceuticals Llc | Nucleotides for the treatment of liver cancer |
US20170101431A1 (en) * | 2014-05-28 | 2017-04-13 | Idenix Pharmaceuticals Llc | Nucleoside derivatives for the treatment of cancer |
JP2017516779A (ja) * | 2014-05-28 | 2017-06-22 | アイデニクス・ファーマシューティカルズ・エルエルシー | 癌治療のためのヌクレオシド誘導体 |
AU2015352203B2 (en) | 2014-11-28 | 2019-08-15 | NuCana plc | New 2' and/or 5' amino-acid ester phosphoramidate 3'-deoxy adenosine derivatives as anti-cancer compounds |
MY190867A (en) | 2015-03-06 | 2022-05-13 | Atea Pharmaceuticals Inc | ? -d-2'-deoxy-2'-?-fluoro-2'- ? -c-substituted-2-modified-n6-substituted purine nucleotides for hcv treatment |
AU2016355429B2 (en) | 2015-11-16 | 2021-05-06 | Cerecor, Inc. | Nucleic acid prodrugs |
GB201522764D0 (en) * | 2015-12-23 | 2016-02-03 | Nucana Biomed Ltd | Formulations of phosphate derivatives |
GB201609601D0 (en) * | 2016-06-01 | 2016-07-13 | Nucana Biomed Ltd | Phosphoramidate compounds |
GB201609600D0 (en) * | 2016-06-01 | 2016-07-13 | Nucuna Biomed Ltd | Cancer treatments |
GB201609602D0 (en) * | 2016-06-01 | 2016-07-13 | Nucuna Biomed Ltd | Chemical compounds |
LU100724B1 (en) | 2016-07-14 | 2018-07-31 | Atea Pharmaceuticals Inc | Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection |
EA037868B1 (ru) | 2016-09-07 | 2021-05-28 | Атеа Фармасьютикалс, Инк. | 2'-замещенные-n6-замещенные пуриновые нуклеотиды для лечения вызванных рнк-вирусом заболеваний |
US11202792B2 (en) | 2016-10-12 | 2021-12-21 | Georgetown University | CD99 inhibitors and their uses |
GB201709471D0 (en) * | 2017-06-14 | 2017-07-26 | Nucana Biomed Ltd | Diastereoselective synthesis of hosphate derivatives |
GB201715011D0 (en) | 2017-09-18 | 2017-11-01 | Nucana Biomed Ltd | Floxuridine synthesis |
GB201720279D0 (en) | 2017-12-05 | 2018-01-17 | Nucana Biomed Ltd | Anticancer compounds |
GB201904544D0 (en) | 2019-04-01 | 2019-05-15 | NuCana plc | Anticancer compounds |
US10874687B1 (en) | 2020-02-27 | 2020-12-29 | Atea Pharmaceuticals, Inc. | Highly active compounds against COVID-19 |
WO2021173713A1 (en) | 2020-02-27 | 2021-09-02 | Atea Pharmaceuticals, Inc. | Highly active compounds against covid-19 |
CN113549076B (zh) * | 2021-07-23 | 2022-12-06 | 中国药科大学 | 一种多取代嘌呤类化合物及其制备方法和应用 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR880000094B1 (ko) | 1984-12-07 | 1988-02-23 | 보령제약 주식회사 | 뉴클레오시드 유도체의 제조방법 |
CA2004695C (en) | 1988-12-12 | 1999-08-10 | Rosanne Bonjouklian | Phospholipid nucleosides |
DE4418690A1 (de) | 1994-05-28 | 1996-01-11 | Boehringer Mannheim Gmbh | Neue Lipidester von Nucleosid-Monophosphaten und deren Verwendung als immunsuppressive Arzneimittel |
GB9505025D0 (en) * | 1995-03-13 | 1995-05-03 | Medical Res Council | Chemical compounds |
CA2675757C (en) | 1995-04-21 | 2011-03-15 | University Of South Florida | Immunopotentiating inosine monophosphate 5'-nucleotidase resistant derivatives and uses thereof |
JP3761958B2 (ja) | 1996-03-12 | 2006-03-29 | 彰 松田 | 3′−カルバモイルアルキルヌクレオシド誘導体 |
DE69900841T2 (de) * | 1998-01-23 | 2002-10-02 | Newbiotics Inc | Durch enzymkatalyse erhaltene therapeutische substanzen. |
GB9821058D0 (en) * | 1998-09-28 | 1998-11-18 | Univ Cardiff | Chemical compound |
JP4768909B2 (ja) | 2000-09-29 | 2011-09-07 | 扶桑薬品工業株式会社 | トポイソメラーゼ阻害剤 |
US20030073618A1 (en) * | 2001-02-08 | 2003-04-17 | Kozhemyakin Leonid A. | Compounds comprising disulfide-containing peptides and nitrogenous bases, and medical uses thereof |
DE10108851A1 (de) * | 2001-02-23 | 2002-09-12 | Resprotect Gmbh | Verwendung von 5'-substituierten Nukleosiden und/oder deren Prodrugs zur resistenzfreien Therapie von Infektionskrankheiten |
EP1478322A4 (en) * | 2001-06-22 | 2007-08-08 | Pharmasset Ltd | Beta 2'-OR 3'-HALONUCLEOSIDE |
GB0317009D0 (en) * | 2003-07-21 | 2003-08-27 | Univ Cardiff | Chemical compounds |
GB0401088D0 (en) | 2004-01-19 | 2004-02-18 | Univ Cardiff | Phosphoramidate derivatives |
US20070265222A1 (en) * | 2004-06-24 | 2007-11-15 | Maccoss Malcolm | Nucleoside Aryl Phosphoramidates for the Treatment of Rna-Dependent Rna Viral Infection |
CN101287472B (zh) * | 2005-08-15 | 2011-10-12 | 弗·哈夫曼-拉罗切有限公司 | 抗病毒的4'-取代前核苷酸的氨基磷酸酯类化合物 |
-
2005
- 2005-03-21 GB GBGB0505781.5A patent/GB0505781D0/en not_active Ceased
-
2006
- 2006-03-16 JP JP2008502453A patent/JP5345381B2/ja not_active Expired - Fee Related
- 2006-03-16 ZA ZA200709011A patent/ZA200709011B/xx unknown
- 2006-03-16 WO PCT/GB2006/000932 patent/WO2006100439A1/en active Application Filing
- 2006-03-16 EP EP06710096A patent/EP1866324B1/en active Active
- 2006-03-16 PT PT06710096T patent/PT1866324E/pt unknown
- 2006-03-16 US US11/886,931 patent/US8263575B2/en active Active
- 2006-03-16 ES ES06710096T patent/ES2348741T3/es active Active
- 2006-03-16 DK DK06710096.6T patent/DK1866324T3/da active
- 2006-03-16 CA CA2602324A patent/CA2602324C/en active Active
- 2006-03-16 AT AT06710096T patent/ATE471334T1/de active
- 2006-03-16 MX MX2007011666A patent/MX2007011666A/es active IP Right Grant
- 2006-03-16 CN CNA200680016708XA patent/CN101175763A/zh active Pending
- 2006-03-16 BR BRPI0609704A patent/BRPI0609704B8/pt active IP Right Grant
- 2006-03-16 DE DE602006014949T patent/DE602006014949D1/de active Active
- 2006-03-16 PL PL06710096T patent/PL1866324T3/pl unknown
- 2006-03-16 SI SI200630762T patent/SI1866324T1/sl unknown
- 2006-03-16 AU AU2006226182A patent/AU2006226182C1/en active Active
- 2006-03-16 CN CN201410186829.5A patent/CN103936807A/zh active Pending
-
2007
- 2007-09-20 IL IL186104A patent/IL186104A/en active IP Right Grant
-
2010
- 2010-09-10 CY CY20101100826T patent/CY1111538T1/el unknown
-
2013
- 2013-05-07 JP JP2013097919A patent/JP5863702B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
ZA200709011B (en) | 2009-01-28 |
JP2013173786A (ja) | 2013-09-05 |
AU2006226182B2 (en) | 2011-09-01 |
JP5345381B2 (ja) | 2013-11-20 |
MX2007011666A (es) | 2007-11-14 |
AU2006226182A1 (en) | 2006-09-28 |
EP1866324B1 (en) | 2010-06-16 |
ES2348741T3 (es) | 2010-12-13 |
DE602006014949D1 (de) | 2010-07-29 |
CA2602324A1 (en) | 2006-09-28 |
PL1866324T3 (pl) | 2010-12-31 |
US8263575B2 (en) | 2012-09-11 |
IL186104A (en) | 2013-06-27 |
BRPI0609704A2 (pt) | 2010-04-20 |
CN101175763A (zh) | 2008-05-07 |
CA2602324C (en) | 2015-02-24 |
JP5863702B2 (ja) | 2016-02-17 |
CY1111538T1 (el) | 2015-08-05 |
BRPI0609704B8 (pt) | 2021-09-28 |
CN103936807A (zh) | 2014-07-23 |
JP2008533191A (ja) | 2008-08-21 |
DK1866324T3 (da) | 2010-09-27 |
SI1866324T1 (sl) | 2010-10-29 |
WO2006100439A1 (en) | 2006-09-28 |
ATE471334T1 (de) | 2010-07-15 |
EP1866324A1 (en) | 2007-12-19 |
PT1866324E (pt) | 2010-09-16 |
US20090215715A1 (en) | 2009-08-27 |
GB0505781D0 (en) | 2005-04-27 |
AU2006226182C1 (en) | 2012-06-14 |
IL186104A0 (en) | 2008-01-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0609704B1 (pt) | compostos derivados de fosforamidato, seus usos, composições farmacêuticas que os compreendem, métodos de preparação das referidas composições e processo para preparação de um composto | |
US20220033433A1 (en) | Process for preparing nucleoside prodrugs | |
ES2906299T3 (es) | Compuestos di-nucleótidos cíclicos para el tratamiento del cáncer | |
JP5271913B2 (ja) | 化合物 | |
ES2708570T3 (es) | Compuestos químicos | |
WO2024120466A1 (en) | Monosaccarides, pharmaceutical compositions, and diagnostic and therapeutic applications | |
WO2024120467A1 (en) | Phosphoramidate monosaccharides, pharmaceutical compositions, and diagnostic and therapeutic applications | |
BR112015011155B1 (pt) | Composição farmacêutica compreendendo uma mistura de rp/sp gemcitabina-[fenil- benziloxi-1- alaninil)]-fosfato |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25A | Requested transfer of rights approved |
Owner name: CARDIFF PROTIDES LIMITED (GB) |
|
B25A | Requested transfer of rights approved |
Owner name: NUCANA BIOMED LIMITED (GB) |
|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 01/12/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 16/03/2006 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: REF. RPI 2604 DE 01/12/2020 QUANTO AO TITULAR (ITEM 73). |
|
B25D | Requested change of name of applicant approved |
Owner name: NUCANA PLC (GB) |
|
B25G | Requested change of headquarter approved |
Owner name: NUCANA PLC (GB) |